very impressive performance in all front including 207% revenue growth. can't believe that share price still took a hit.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
TLS Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago